Biomarin Pharmaceutical reported $402.39M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
Acorda Therapeutics ACOR:US $ 16.57M 16.2M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Amgen AMGN:US $ 4677M 451M
Bayer BAYN:GR 9.46B 2.03B
Biogen BIIB:US $ 1777.9M 295.8M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Gilead Sciences GILD:US $ 5166M 549M
Insmed INSM:US $ 40.92M 1.92M
Intercept Pharmaceuticals ICPT:US $ 87.82M 3.57M
IONIS PHARMACEUT IONS:US $ 137.75M 300.03M
Moderna Inc MRNA:US 5.05B 1.21B
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Ptc Therapeutics PTCT:US $ 138.6M 17.3M
Puma Biotechnology PBYI:US $ 34.89M 8.57M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Seattle Genetics SGEN:US $ 338.83M 4.33M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
United Therapeutics UTHR:US $ 436M 55.4M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M
YTE INCY:US $ 696.02M 128.26M